<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/25/global-blood-therapeutics-gbt-buy-rating-reaffirmed-at-cantor-fitzgerald.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-25T08:22:42+00:00"/>
    <meta property="og:title" content="Global Blood Therapeutics’ (GBT) Buy Rating Reaffirmed at Cantor Fitzgerald"/>
    <meta property="og:description" content="Global Blood Therapeutics (NASDAQ:GBT)‘s stock had its “buy” rating reissued by Cantor Fitzgerald in a research report issued on Monday, AnalystRatings.com reports. They currently have a $98.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 74.56% from the stock’s previous close. Several other analysts also recently issued reports […]"/>
  </head>
  <body>
    <article>
      <h1>Global Blood Therapeutics’ (GBT) Buy Rating Reaffirmed at Cantor Fitzgerald</h1>
      <address><time datetime="2019-11-25T08:22:42+00:00">25 Nov 2019, 08:22</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/global-blood-therapeutics-inc-logo.png"/>
      </figure>
      <p>Global Blood Therapeutics (NASDAQ:GBT)‘s stock had its “buy” rating reissued by Cantor Fitzgerald in a research report issued on Monday, <a href="https://www.analystratings.com/articles/cantor-fitzgerald-sticks-to-its-buy-rating-for-global-blood-therapeutics-gbt//">AnalystRatings.com</a> reports. They currently have a $98.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 74.56% from the stock’s previous close.</p>
      <p>Several other analysts also recently issued reports on GBT. Wedbush restated a “buy” rating and set a $120.00 price objective on shares of Global Blood Therapeutics in a report on Wednesday, October 9th. Canaccord Genuity began coverage on Global Blood Therapeutics in a report on Wednesday, November 6th. They set a “hold” rating and a $50.00 price objective on the stock. BidaskClub upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Wells Fargo &amp; Co boosted their price objective on Global Blood Therapeutics from $96.00 to $104.00 and gave the stock an “outperform” rating in a report on Wednesday, October 9th. Finally, HC Wainwright restated a “buy” rating and set a $150.00 price objective on shares of Global Blood Therapeutics in a report on Wednesday, October 9th. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Global Blood Therapeutics currently has an average rating of “Buy” and an average target price of $87.15.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/GBT/price-target/">GBT stock</a> opened at $56.14 on Monday. Global Blood Therapeutics has a fifty-two week low of $30.15 and a fifty-two week high of $64.94. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $3.37 billion, a P/E ratio of -16.46 and a beta of 1.57. The company has a 50-day simple moving average of $49.21 and a 200 day simple moving average of $53.04.</p>
      <p>Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.03) by ($0.04). During the same quarter in the prior year, the business earned ($0.83) EPS. Equities analysts anticipate that Global Blood Therapeutics will post -4.12 EPS for the current year.</p>
      <p>In other Global Blood Therapeutics news, insider Joshua Lehrer-Graiwer sold 6,562 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $55.00, for a total transaction of $360,910.00. Following the completion of the sale, the insider now owns 656 shares of the company’s stock, valued at $36,080. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through <a href="https://www.sec.gov/Archives/edgar/data/1629137/000089924319027721/xslF345X03/doc4.xml">the SEC website</a>. Also, insider Lesley Ann Calhoun sold 2,765 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $54.36, for a total value of $150,305.40. Following the sale, the insider now directly owns 887 shares of the company’s stock, valued at approximately $48,217.32. The disclosure for this sale can be found <a href="https://www.sec.gov/Archives/edgar/data/1629137/000089924319023567/xslF345X03/doc4.xml">here</a>. Insiders have sold 21,589 shares of company stock valued at $1,088,421 in the last ninety days. Company insiders own 4.30% of the company’s stock.</p>
      <p>Institutional investors and hedge funds have recently bought and sold shares of the company. Prudential Financial Inc. boosted its position in shares of Global Blood Therapeutics by 11.1% in the second quarter. Prudential Financial Inc. now owns 5,623 shares of the company’s stock valued at $296,000 after acquiring an additional 560 shares during the period. Janney Montgomery Scott LLC raised its stake in shares of Global Blood Therapeutics by 56.3% in the second quarter. Janney Montgomery Scott LLC now owns 7,590 shares of the company’s stock valued at $399,000 after purchasing an additional 2,735 shares in the last quarter. Taylor Wealth Management Partners raised its stake in shares of Global Blood Therapeutics by 2.1% in the third quarter. Taylor Wealth Management Partners now owns 45,726 shares of the company’s stock valued at $2,219,000 after purchasing an additional 925 shares in the last quarter. Eagle Asset Management Inc. raised its stake in shares of Global Blood Therapeutics by 2.1% in the third quarter. Eagle Asset Management Inc. now owns 446,011 shares of the company’s stock valued at $21,640,000 after purchasing an additional 9,050 shares in the last quarter. Finally, Advisor Group Inc. raised its stake in shares of Global Blood Therapeutics by 1,307.9% in the second quarter. Advisor Group Inc. now owns 11,404 shares of the company’s stock valued at $600,000 after purchasing an additional 10,594 shares in the last quarter. 97.96% of the stock is owned by institutional investors.</p>
      <p>
        <b>About Global Blood Therapeutics</b>
      </p>
      <p>Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/day-trading--risk-or-reward/">How much money do you need to begin day trading?</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=GBT"/>
      </figure>
    </article>
  </body>
</html>